Replimune Group (NASDAQ:REPL – Free Report) had its target price decreased by Barclays from $50.00 to $13.00 in a research report report published on Wednesday morning, Benzinga reports. Barclays currently has an overweight rating on the stock. A number of other brokerages also recently weighed in on REPL. Wedbush reaffirmed an outperform rating and issued […]
Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) have received an average recommendation of “Buy” from the six analysts that are covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued a report on the stock in […]
Integral Health Asset Management LLC increased its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 79.5% during the 1st quarter, Holdings Channel.com reports. The fund owned 395,000 shares of the company’s stock after acquiring an additional 175,000 shares during the period. Integral Health Asset Management LLC’s holdings in Replimune Group were […]
Integral Health Asset Management LLC lifted its stake in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 79.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 395,000 shares of the company’s stock after acquiring an additional 175,000 shares during the […]
Emerald Mutual Fund Advisers Trust lessened its position in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 16.8% during the 1st quarter, Holdings Channel reports. The firm owned 803,448 shares of the company’s stock after selling 162,490 shares during the quarter. Emerald Mutual Fund Advisers Trust’s holdings in Replimune Group were worth $14,189,000 at the […]